Electroencephalographic signatures of dysfunctional cerebrovascular autoregulation as biomarkers of brain injury in aneurysmal subarachnoid hemorrhage (SAH)

脑血管自动调节功能障碍的脑电图特征作为动脉瘤性蛛网膜下腔出血（SAH）脑损伤的生物标志物

• 批准号: 10667162
• 负责人: Jennifer A Kim
• 金额: $ 25.13万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-15 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10667162
• 关键词: Acute; Adult; Affect; Aneurysmal Subarachnoid Hemorrhages; Benchmarking; Biological Markers; Blood Pressure; Blood Vessels; Brain; Brain Injuries; Brain hemorrhage; Caring; Cerebral Ischemia; Cerebral hemisphere hemorrhage; Cerebral perfusion pressure; Cerebrovascular Circulation; Cerebrovascular Disorders; Cerebrovascular Spasm; Cerebrum; Clinical; Clinical Trials; Cohort Studies; Compensation; Complication; Coupled; Critical Illness; Data; Detection; Deterioration; Development; Disabled Persons; Disease; Distress; Early Diagnosis; Early Intervention; Electroencephalography; Exogenous Factors; Failure; Fright; Functional disorder; Future; Goals; Hemorrhage; Homeostasis; Individual; Informatics; Infrastructure; Intervention; Intracranial Pressure; Ischemia; Ischemic Stroke; Knowledge; Link; Metabolic; Metabolism; Mission; Modeling; Monitor; Morbidity - disease rate; Nature; Near-Infrared Spectroscopy; Nervous System Trauma; Neurologic; Neurologic Deficit; Neurology; Neurons; Operative Surgical Procedures; Outcome; Patients; Pattern; Perfusion; Phase; Phenotype; Physiological; Physiology; Play; Principal Investigator; Protocols documentation; Quality of life; Recovery; Research; Research Proposals; Resources; Rest; Risk; Risk Assessment; Ruptured Aneurysm; Sedation procedure; Signal Transduction; Stroke; Subarachnoid Hemorrhage; Subarachnoid Space; Survivors; Technology; Testing; Therapeutic; Time; Transcranial Doppler Ultrasonography; United States; United States National Institutes of Health; Vasospasm; biomarker driven; blood pressure control; cerebral hemodynamics; cerebral hypoperfusion; cerebrovascular; clinical center; clinical investigation; clinical practice; cohort; data repository; diagnostic strategy; disability; epileptiform; exhaust; functional improvement; functional outcomes; high risk; hypoperfusion; improved; individual patient; innovation; insight; nervous system disorder; neurophysiology; neuroprotection; neurovascular; novel; personalized approach; personalized medicine; pharmacologic; population based; precision medicine; pressure; prevent; prospective; risk mitigation; signal processing; tissue oxygenation; tool; treatment strategy

Abstract Aneurysmal subarachnoid hemorrhage (aSAH) remains a devastating disease affecting approximately 30,000 adults in the United States per year. Forty percent of aSAH patients die within 30 days, and over one-third of survivors sustain major neurologic deficits, in part due to feared secondary complications like vasospasm and delayed cerebral ischemia (DCI). Despite advances in care, few interventions can mitigate the risk of neurologic worsening after the initial bleed, and current monitoring strategies to identify impending DCI have limited accuracy. Abnormalities in cerebrovascular autoregulation and flow-metabolism uncoupling in the acute phase after aSAH have been shown to increase the risk of secondary brain injury and likely represent key players in the development of DCI. In this proposal, we plan to develop and refine an innovative, personalized approach to blood pressure management to identify patients most likely to benefit from therapeutic BP manipulation. To carry out this overarching aim, we will track continuous recordings of intracranial pressure, near-infrared spectroscopy, and EEG to determine patient-specific blood pressure targets that yield optimal brain blood flow and metabolism. This research proposal will evaluate if cerebral hemodynamic dysregulation drives EEG deterioration (Aim 1) and if a deviation from optimized blood pressure targets is associated with DCI and poor outcomes (Aim 2). We will then prospectively validate our results in a pilot cohort study. This proposal’s feasibility rests on (1) several years of research conducted by the principal investigators on signal processing, autoregulatory physiology, and continuous EEG in disease states like SAH and ischemic stroke, and (2) promising preliminary analyses evaluating the hypotheses being explored in this proposal. In total, this autoregulation-oriented neuroprotective therapy aims to optimize cerebral perfusion and ultimately improve clinical and functional outcomes. This research proposal is thus directly aligned with the NIH mission to reduce the burden of neurological disorders and enhance the quality of life of people with disabilities. The study will leverage Yale’s cutting-edge neuro- monitoring technologies along with extensive informatics and research resources of the Yale Center for Clinical Investigation to generate new insights into cerebral hemodynamics after aSAH and identify treatment opportunities. This line of research is readily translatable to the bedside and also applies to other cerebrovascular diseases like intracerebral hemorrhage and ischemic stroke, both of which likely encompass dysautoregulation as a critical physiologic variable. Knowledge gained in this study is anticipated to lead to a significant shift in the treatment approach for aSAH patients. It may ultimately lead to a clinical trial testing autoregulation-based treatment strategies, including tailored pharmacologic BP modulation based on patients’ real-time autoregulatory status. Our long-term goal is to use neuro-monitoring to develop physiology-based, personalized, early interventions to reduce the disability and morbidity associated with neurologic injury.

抽象的 动脉瘤性蛛网膜下腔出血 (aSAH) 仍然是一种毁灭性的疾病，影响着大约 30,000 人 美国每年有 40% 的 aSAH 患者在 30 天内死亡，其中超过三分之一的患者会在 30 天内死亡。 幸存者承受着严重的神经功能缺陷，部分原因是由于担心血管痉挛等继发性并发症 尽管护理方面取得了进步，但很少有干预措施可以降低神经系统风险。 初次出血后病情恶化，目前识别即将发生的 DCI 的监测策略有限 急性期脑血管自动调节和血流代谢解偶联的异常。 aSAH 已被证明会增加继发性脑损伤的风险，并且可能代表了这一领域的关键参与者 在本提案中，我们计划开发和完善一种创新的、个性化的方法。 血压管理以确定最有可能从治疗性血压控制中受益的患者。 为了实现这一总体目标，我们将跟踪颅内压、近红外光谱、 和脑电图来确定患者特定的血压目标，从而产生最佳的脑血流和新陈代谢。 该研究计划将评估脑血流动力学失调是否导致脑电图恶化（目标 1） 偏离最佳血压目标是否与 DCI 和不良结果相关（目标 2）。 然后，我们将在一项试点队列研究中前瞻性地验证我们的结果。该提案的可行性取决于（1）几个方面。 主要研究人员在信号处理、自动调节生理学和 SAH 和缺血性中风等疾病状态下的连续脑电图，以及 (2) 有希望的初步分析 评估本提案中正在探索的假设。总的来说，这种以自我调节为导向的神经保护作用。 治疗旨在优化脑灌注并最终改善临床和功能结果。 因此，研究提案与 NIH 减轻神经系统疾病负担的使命直接相关 该研究将利用耶鲁大学的尖端神经科学技术来提高残疾人的生活质量。 监测技术以及耶鲁临床中心的广泛信息学和研究资源 研究旨在对 aSAH 后脑血流动力学产生新的见解并确定治疗方法 这一系列研究很容易转化为临床，也适用于其他脑血管疾病。 脑出血和缺血性中风等疾病，这两种疾病都可能涉及自动调节障碍 作为一个关键的生理变量，预计本研究中获得的知识将导致显着的转变。 aSAH 患者的治疗方法最终可能会导致基于自动调节的临床试验。 治疗策略，包括基于患者实时自动调节的定制药物血压调节 我们的长期目标是利用神经监测来开发基于生理学的、个性化的、早期的治疗。 减少与神经损伤相关的残疾和发病率的干预措施。